Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab

Kimio Yonesaka, Kreshnik Zejnullahu, Isamu Okamoto, Taroh Satoh, Federico Cappuzzo, John Souglakos, Dalia Ercan, Andrew Rogers, Massimo Roncalli, Masayuki Takeda, Yasuhito Fujisaka, Juliet Philips, Toshio Shimizu, Osamu Maenishi, Yonggon Cho, Jason Sun, Annarita Destro, Koichi Taira, Koji Takeda, Takafumi OkabeJeffrey Swanson, Hiroyuki Itoh, Minoru Takada, Eugene Lifshits, Kiyotaka Okuno, Jeffrey A. Engelman, Ramesh A. Shivdasani, Kazuto Nishio, Masahiro Fukuoka, Marileila Varella-Garcia, Kazuhiko Nakagawa, Pasi A. Jänne

Research output: Contribution to journalArticlepeer-review

398 Citations (Scopus)

Fingerprint Dive into the research topics of 'Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab'. Together they form a unique fingerprint.

Medicine & Life Sciences